Phoenix Biotech Acquisition Corp.
Status: Closed Deal
U=S+W/2
W=S@11.50
| IPO Proceeds, $M | $175.00M |
|---|---|
| IPO Date | Oct 6, 2021 |
| CEO | Chris Ehrlich |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 102.0% |
| SPAC Tenor | 15 + 6 + 6 + 3 |
| IPO Sector | Healthcare ▶ |
| IPO Geography | Global |
| Target Company | CERo Therapeutics |
| Deal Announced | Jun 5, 2023 |
| Deal Size, $M | $145.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Feb 8, 2024 |
| Amendment Vote | Jan 3, 2024 |
| Closing Date | Feb 14, 2024 |
Formerly PBAX
CERO
CEROW
| Price | $0.08 $0.00 |
|---|---|
| Last closing price | $0.10 |
| H/L, today | $0.07 / $0.08 |
| Volume, today | 287,178 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.